Cue Biopharma (CUE) Operating Expenses (2017 - 2025)
Cue Biopharma (CUE) posted Operating Expenses of $20.0 million for Q4 2025, up 104.89% sequentially from $9.7 million in Q3 2025, and up 78.11% YoY from $11.2 million in Q4 2024.
Cue Biopharma (CUE) Operating Expenses (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Operating Expenses for 9 years, with the latest figure at $20.0 million in Q4 2025.
- Quarterly Operating Expenses rose 78.11% year-over-year to $20.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $54.0 million (up 6.36% YoY) and the FY2025 annual result came in at $54.0 million, up 6.36% from the prior year.
- Operating Expenses advanced to $20.0 million in Q4 2025 per CUE's latest filing, from $9.7 million in the prior quarter.
- Over five years, Operating Expenses peaked at $20.0 million in Q4 2025 and troughed at $9.7 million in Q3 2025.
- A 5-year average of $13.8 million and a median of $13.5 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses slipped 28.39% in 2024, then soared 78.11% in 2025.
- Over 5 years, Operating Expenses stood at $16.1 million in 2021, then slipped by 7.0% to $15.0 million in 2022, then gained by 4.24% to $15.7 million in 2023, then retreated by 28.39% to $11.2 million in 2024, then jumped by 78.11% to $20.0 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $20.0 million, $9.7 million, and $11.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 95.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.96 Mn |
| Sep 30, 2025 | 9.74 Mn |
| Jun 30, 2025 | 11.59 Mn |
| Mar 31, 2025 | 12.72 Mn |
| Dec 31, 2024 | 11.21 Mn |
| Sep 30, 2024 | 12.15 Mn |
| Jun 30, 2024 | 13.04 Mn |
| Mar 31, 2024 | 14.39 Mn |
| Dec 31, 2023 | 15.65 Mn |
| Sep 30, 2023 | 13.52 Mn |
| Jun 30, 2023 | 14.90 Mn |
| Mar 31, 2023 | 13.57 Mn |
| Dec 31, 2022 | 15.02 Mn |
| Sep 30, 2022 | 11.10 Mn |
| Jun 30, 2022 | 13.12 Mn |
| Mar 31, 2022 | 15.24 Mn |
| Dec 31, 2021 | 16.15 Mn |
| Sep 30, 2021 | 15.41 Mn |
| Jun 30, 2021 | 13.04 Mn |
| Mar 31, 2021 | 14.07 Mn |